Norgine's Performance in 2017 and Priorities for 2018

AMSTERDAM, February 26, 2018 /PRNewswire/ --

• Continues long track record of growth. 2017 Net Sales were ?345million, up 17 per cent 
• Receives European approval and launch PLENVU^® 
• Strengthens its position with the acquisition of Merus Labs International Inc. for C$342m 
• Norgine's products used by over 15 million patients  

Norgine continues to execute its Vision 2020:

• drive the performance of its products through its European and Australian infrastructure
• accelerate its growth strategy

     (Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )

PRODUCTS 

In house products: 

• MOVICOL^® - despite generic competition our leading anti-constipation product maintained its leading position with sales declining slightly to ?157million (2016: ?159million)

• MOVIPREP^® - our 2Litre bowel preparation for colonoscopy - achieved sales of ?57million, up 7% (2016: ?53million)

• PLENVU^® - received European approval and launched the first 1Litre bowel preparation for colonoscopy

Key in-licensed products: 

• XIFAXAN^®  - our hepatic encephalopatic treatment - saw sales of ?51million, up 24% (2016: ?41million)

• LYMPHOSEEK^® - new radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity - launched in Denmark, the Netherlands and the UK

Key acquired products: 

• Merus Labs International Inc. portfolio - acquired 12 established products including SINTROM^®, EMSELEX^®, ELANTAN^®, ISOKET^®, DEPONIT^®, SALAGEN^® and ESTRADERM^® which are sold across Europe and in other selected markets and VANCOCIN^® which is sold in Canada. Contributed to ?31million since acquisition on 17 July 2017

NORGINE  STRENGHTENS ITS POSTION AS THE 'GO TO' EU SPECIALIST PHARMA COMPANY PARTNER OF CHOICE  

• Merus Labs International Inc. This acquisition increased Norgine's scale and profitability, helping to strengthen the business and attract new opportunities in the future

• Apharm s.r.l. Norgine expanded its partnership with Apharm s.r.l by entering into an exclusive distribution deal for ZIVEREL^® PLUS, a line extension of ZIVEREL^®. This deal expands on Norgine's existing collaboration with Apharm s.r.l. under which Norgine is distributing ZIVEREL^® in Europe, Australia and New Zealand

Peter Stein, CEO of Norgine: "2017 was a transformational year for Norgine. We successfully executed our strategy as the European Specialist Pharma Company to grow like for like sales of our existing products, gain approval of PLENVU^® in Europe and acquire and integrate Merus Labs International Inc. Our strategy is working. We have a solid foundation for sustained growth in revenue and profitability. 2018 is a year of acceleration for Norgine. We will continue to focus on maximising the sales of our existing products while also pursuing new opportunities to bring transformative products to patients".

Video - https://youtu.be/g1LMgln1O2o

Listen to Peter Stein, CEO of Norgine discussing 2017 performance and 2018 objectives  

Media Contact: 

Isabelle Jouin, T: +44(0)1895-453643

Follow us @norgine 

View the full press release on http://www.norgine.com/media